Victoria Johnson

The vice president research and chair of internal medicine at the University of Erlangen – Nuremberg discussed findings from 2 early studies of CD19 CAR T-cell therapy.

As cell therapy investigations mature in the field of AD, some programs show promising signs of efficacy.

Atsena announced initial positive data from the LIGHTHOUSE study of ATSN-201 in May 2024.

A patient with MG is also the first evaluated to reach 1 year of follow-up and has a continued durable immunomodulator-free response.

The president and chief executive officer of Passage Bio discussed feedback from a recent Type C meeting with the FDA.

TRX103 is also being evaluated for the prevention of graft versus host disease (GvHD) in patients undergoing HLA-mismatched HSCT.

The chief medical officer at Creyon Bio discussed future applications for the company’s AI-guided discovery platform.

NGN-401 is being evaluated in an early phase clinical trial which has been selected for the FDA’s START Pilot Program.

Elderly patients were at higher risk of infections and subsequent malignant neoplasms.

Participants are being dosed with OCU400 in the ongoing phase 3 liMeliGhT trial.

The cofounder and chief science officer of Longeveron discussed working to show potential benefits in a follow-up phase 3 trial.

The trial evaluating the safety and tolerability of IDP-023 will be led by Stanford and UCSF.

A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.

The chief medical officer at Creyon Bio discussed findings from a treated patient with a TNP02 missense mutation.

BriaCell initiated the pivotal phase 3 BRIA-ABC trial in October 2023.

At the selected phase 2 dose, 76% of patients were injection free, with maintained visual acuity and fluid control.

BioNTech is evaluating BNT111 in a phase 2 trial, primary analysis data from which will be presented in a future medical conference.

The company has filed a protocol amendment with the EMA and anticipates resuming recruitment imminently.

OBX-115 recently demonstrated a 50% ORR at doses over 30 × 109 cells at 29.5 weeks after infusion.

There were no new cases of CRS past 2 weeks after infusion and non-relapse mortality was driven by infection in follow-up.

The chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.

CT-0525 is being evaluated in a phase 1 clinical trial currently enrolling participants.

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

Ractigen is also evaluating saRNA therapies for ALS and SMA.

The cofounder and chief science officer of Longeveron discussed updated data from the phase 2a CLEAR MIND study.

The European Commission granted conditional marketing authorization under the name Beqvez to the European Union.

There were no serious adverse events related to the cell therapy and no evidence of ARIA.

Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies, Dana-Farber Cancer Institute, discussed GPRC5D-targeted CAR-T, BMS-986393.

The company acquired the program, along with Spark Therapeutics’ pipeline, in December 2019.

IASO also received IND clearance for a trial in myasthenia gravis in April 2024.